These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 15089028)

  • 21. Not different is not the same as the same: how can we tell?
    Drummond GB; Vowler SL
    Microcirculation; 2012 Nov; 19(8):771-4. PubMed ID: 23164036
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparing two small samples with an unstable, treatment-independent baseline.
    Janusonis S
    J Neurosci Methods; 2009 May; 179(2):173-8. PubMed ID: 19428524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of statistical methods in dental research: comparison of four dental journals during a 10-year period.
    Vähänikkilä H; Nieminen P; Miettunen J; Larmas M
    Acta Odontol Scand; 2009; 67(4):206-11. PubMed ID: 19308754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Not different is not the same as the same: how can we tell?
    Drummond GB; Vowler SL
    Exp Physiol; 2013 Feb; 98(2):351-4. PubMed ID: 23349528
    [No Abstract]   [Full Text] [Related]  

  • 25. Methodology, measures and the clinician.
    Ricci S
    Cerebrovasc Dis; 2012; 33(2):97. PubMed ID: 22327265
    [No Abstract]   [Full Text] [Related]  

  • 26. Sample size and power.
    Haas JP
    Am J Infect Control; 2012 Oct; 40(8):766-7. PubMed ID: 23021415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Construction of group sequential designs in clinical trials on the basis of detectable treatment differences.
    Schäfer H; Müller HH
    Stat Med; 2004 May; 23(9):1413-24. PubMed ID: 15116350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. On effect size.
    Kelley K; Preacher KJ
    Psychol Methods; 2012 Jun; 17(2):137-52. PubMed ID: 22545595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal sampling in retrospective logistic regression via two-stage method.
    Chien CY; Ivan Chang YC; Hsueh HM
    Biom J; 2011 Feb; 53(1):5-18. PubMed ID: 21259305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alpha values as a function of sample size, effect size, and power: accuracy over inference.
    Bradley MT; Brand A
    Psychol Rep; 2013 Jun; 112(3):835-44. PubMed ID: 24245076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two confidence interval approaches on the dependability coefficient in a two-factor crossed design.
    Ting N; Cappelleri JC; Bushmakin AG
    J Biopharm Stat; 2009 Jul; 19(4):610-24. PubMed ID: 20183429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statistical considerations on design and analysis of bridging and multiregional clinical trials.
    Tsong Y
    J Biopharm Stat; 2012 Sep; 22(5):1078-80. PubMed ID: 22946952
    [No Abstract]   [Full Text] [Related]  

  • 33. [What to do if statistical power is low? A practical strategy for pre-post-designs].
    Müller J; Manz R; Hoyer J
    Psychother Psychosom Med Psychol; 2002; 52(9-10):408-16. PubMed ID: 12355348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Power, p-value, and sample size].
    Singer S
    Psychother Psychosom Med Psychol; 2010 Aug; 60(8):329-30. PubMed ID: 20697989
    [No Abstract]   [Full Text] [Related]  

  • 35. Mixed noninferiority margin and statistical tests in active controlled trials.
    Tsou HH; Hsiao CF; Chow SC; Yue L; Xu Y; Lee S
    J Biopharm Stat; 2007; 17(2):339-57. PubMed ID: 17365228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minimize the use of minimization with unequal allocation.
    Proschan M; Brittain E; Kammerman L
    Biometrics; 2011 Sep; 67(3):1135-41. PubMed ID: 21281276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statistical perspectives: all together not.
    Hopkins WG; Batterham AM; Impellizzeri FM; Pyne DB; Rowlands DS
    Clin Exp Pharmacol Physiol; 2011 Dec; 38(12):914-6; author reply 917-8. PubMed ID: 21933227
    [No Abstract]   [Full Text] [Related]  

  • 38. Analysis of homogeneity of treatment effect in adaptive multicenter clinical trials.
    Chen L; Tamura RN
    J Biopharm Stat; 1998 Mar; 8(1):55-67. PubMed ID: 9547427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Flexible design of two-stage adaptive procedures for phase III clinical trials.
    Koyama T
    Contemp Clin Trials; 2007 Jul; 28(4):500-13. PubMed ID: 17307399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A generalized concept of power helped to choose optimal endpoints in clinical trials.
    Borm GF; van der Wilt GJ; Kremer JA; Zielhuis GA
    J Clin Epidemiol; 2007 Apr; 60(4):375-81. PubMed ID: 17346612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.